Taken together, our findings show that NXP800 demonstrates antitumor activity in treatment-resistant prostate cancer models, acting through a novel mechanism of action that has the potential to provide a new therapeutic strategy for hard-to-treat prostate cancer tumors with persistent AR signaling and high E2F activity, supporting its consideration for prostate cancer–specific clinical development. The gene discussed is AR; the disease is prostate carcinoma.